FolusoOlabisiAdemuyiwaMD

Oncology • Saint Louis, MO

Breast Cancer, Hematologic Oncology

Associate Professor, Internal Medicine, Washington University in St. Louis School of Medicine

Join to view full profile

Dr. Ademuyiwa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ademuyiwa's full profile

Already have an account?

Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110
Phone+1 800-647-2098

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine/Pediatrics, 2002 - 2006
University of IbadanClass of 1999

Awards, Honors, & Recognition

Best Doctor in St Louis 2015-2016

Clinical Trials

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells Start of enrollment: 2013 Dec 19
Terminated
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04
Terminated
Not Applicable
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer Start of enrollment: 2013 Jun 01
Completed
Phase 1
Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity Start of enrollment: 2014 Jul 07
Terminated
Phase 2
Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy Start of enrollment: 2015 Jan 07
Active, not recruiting
Phase 1
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer Start of enrollment: 2017 Jun 30
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.
Michael D Iglesia, Reyka G Jayasinghe, Siqi Chen, Nadezhda V Terekhanova, John M Herndon
Nature Cancer. 2024-10-30
225 citations
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew P. Goetz
Clinical Cancer Research. 2017-08-01
72 citations
NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
Foluso O. Ademuyiwa, Wiam Bshara, Kristopher Attwood, Carl Morrison, Stephen B. Edge
Plos One. 2012-06-28

Press Mentions

Interventions Needed to Support Mammography Attendance Among Black WomenApril 21st, 2021

Professional Memberships